Drug repurposing: Clemastine fumarate and neurodegeneration

Biomed Pharmacother. 2023 Jan:157:113904. doi: 10.1016/j.biopha.2022.113904. Epub 2022 Nov 9.

Abstract

Neurodegenerative diseases have been a weighty problem in elder people who might be stricken with motor or/and cognition defects with lower life quality urging for effective treatment. Drugs are costly from development to market, so that drug repurposing, exploration of existing drugs for novel therapeutic purposes, becomes a wise and popular strategy to raise new treatment options. Clemastine fumarate, different from anti-allergic effect as H1 histamine antagonist, was screened and identified as promising drug for remyelination and autophagy enhancement. Surprisingly, fumarate salt also has similar effect. Hence, whether clemastine fumarate would make a protective impact on neurodegenerative diseases and what contribution fumarate probably makes are intriguing to us. In this review, we summarize the potential mechanism surrounding clemastine fumarate in current literature, and try to distinguish independent or synergistic effect between clemastine and fumarate, aiming to find worthwhile research direction for neurodegeneration diseases.

Keywords: Autophagy; Clemastine; Dimethyl fumarate; Neurodegeneration; Remyelination.

Publication types

  • Review

MeSH terms

  • Aged
  • Anti-Allergic Agents*
  • Clemastine / therapeutic use
  • Drug Repositioning
  • Fumarates
  • Humans
  • Remyelination*

Substances

  • Clemastine
  • Anti-Allergic Agents
  • Fumarates